Phase 3 Clinical Trials With Primary Completion Dates in October 2024

This is a list of Phase 3 trials with primary completion dates in October 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
AGIOAgios Pharmaceuticals, Inc.2024-10-01Phase 3NCT05175105A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
ARCTArcturus Therapeutics Holdings Inc.2024-10-01Phase 3NCT06279871Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
CASBFCanSino Biologics Inc.2024-10-01Phase 3NCT06226714A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds
FULCFulcrum Therapeutics, Inc.2024-10-01Phase 3NCT05397470Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
IMUXImmunic, Inc.2024-10-01Phase 3NCT05201638Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
MTNBMatinas BioPharma Holdings, Inc.2024-10-01Phase 3NCT05541107Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
OTLKOutlook Therapeutics, Inc.2024-10-01Phase 3NCT06190093A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)
SAVACassava Sciences, Inc.2024-10-01Phase 3NCT04994483Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
SRRKScholar Rock Holding Corporation2024-10-01Phase 3NCT05156320Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
VRNAVerona Pharma plc2024-10-01Phase 3NCT06460493Effect of Ensifentrine Treatment on CAT Score